

## COMPANY INFORMATION SHEET

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.*

**Company Name (stock code):** Hansoh Pharmaceutical Group Company Limited (stock code: 3692)

**Stock Short Name:** HANSOH PHARMA/翰森製藥

This information sheet is provided for the purpose of giving information to the public about Hansoh Pharmaceutical Group Company Limited (the “**Company**”) as at the date of this company information sheet. The information does not purport to be a complete summary of information about the Company and/or its securities.

Unless otherwise defined herein, capitalized terms used in this information sheet shall have the same meanings as ascribed to them in the Company’s prospectus dated May 31, 2019 (the “**Prospectus**”) and references to sections of the Prospectus shall be construed accordingly.

### Responsibility Statement

The directors of the Company (the “**Directors**”) as at the date of this company information sheet collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any information inaccurate or misleading herein.

The Directors also collectively and individually undertake to publish a revised company information sheet when there are changes to the company information since the last publication pursuant to Rule 19.60 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

**Date of this information sheet: June 27, 2022**

## Summary of Novel Waiver(s)

The following novel waiver has been applied for and granted by the Stock Exchange. For other waivers applied for and granted by the Stock Exchange, please refer to the section headed “Waivers from Strict Compliance with the Listing Rules” in the Prospectus.

### Relevant Rule Waived

Rule 8.08(1)(a)

### Subject Matter

Public float requirements

### Waiver in Relation to Public Float Requirements

In preparation for the Listing, our Company has applied to the Stock Exchange to request the Stock Exchange to exercise its discretion under Rule 8.08(1)(d) of the Listing Rules, and the Stock Exchange has granted our Company a waiver from strict compliance with the requirements of Rule 8.08(1)(a) of the Listing Rules.

Rule 8.08(1)(a) of the Listing Rules requires that there shall be an open market for the securities for which listing is sought, and that a sufficient public float of an issuer’s listed securities shall be maintained. This normally means that at least 25% of the issuer’s total issued share capital must at all times be held by the public. Pursuant to Rule 8.08(1)(d) of the Listing Rules, the Stock Exchange may, subject to certain conditions and at its discretion, accept a lower percentage of between 15% and 25% in the case of issuers with an expected market capitalization at the time of listing of over HK\$10 billion.

Our market capitalization was no less than HK\$10 billion at the time of Listing.

Accordingly, our minimum public float shall be the highest of:

- (i) 15% of our Company’s total issued share capital;
- (ii) such percentage of Shares to be held by the public immediately after the completion of the Global Offering (assuming that the Over-allotment Option is not exercised); and
- (iii) such percentage of Shares to be held by the public immediately after the completion of the Global Offering (as increased by the Shares to be issued upon any exercise of the Over-allotment Option) provided that the highest of (i), (ii) and (iii) above is below the minimum public requirement of 25% under Rule 8.08(1) of the Listing Rules.

In order to support the application of the waiver, we have confirmed to the Stock Exchange that:

- (i) we would have an expected market capitalization at the time of Listing of over HK\$10 billion;
- (ii) there would be an open market in the Shares, and the quantity and scale of the Shares and the extent of distribution of the Shares would enable the market to operate properly with a lower percentage of public float;
- (iii) we would make appropriate disclosure of the lower percentage of public float as approved by the Stock Exchange in the Prospectus;
- (iv) we would confirm sufficiency of public float in our successive annual reports after the Listing; and
- (v) we would implement appropriate measures and mechanisms to ensure continual maintenance of the minimum percentage of public float.

*As at the date of this document, the board of directors of the Company comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*